

## REMARKS

### Election

Claims 1, 2, 6-10, 12, 13, 16-18 and 21-44 are pending. The office is requiring Applicants to elect a single species, to which the claims shall be restricted if no generic claim is finally held to be allowable, from the following:

Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril and moexipril.

Applicants provisionally elect, with traverse, the single species "quinapril" as the angiotensin converting enzyme inhibitor recited, for example, in pending Claim 30.

Applicants' reasons for traverse are the following:

Each of the pending claims is directed to therapeutic combinations comprising eplerenone and an angiotensin converting enzyme inhibitor. A search of one species likely will overlap with a search of the other species. Accordingly, it would not be unduly burdensome on the Office to collectively search these species.

For these reasons the restriction requirement should be withdrawn.

Applicants further list the following group of pending claims that read on the elected species:


Claims 1, 2, 6-10, 12, 13, 16-18, 21-23, 30, 34 and 41.

\* \* \*

The elected claims should now be in condition for allowance. Favorable consideration and early allowance of these claims is requested. The Commissioner is hereby authorized to charge any fees that may be required during the entire pendency of this application, to Deposit Account No. 19-1025.

Any correspondence in respect to this Application should be sent to the address below and addressed to Joseph R. Schuh.

Respectfully submitted,



---

Joseph R. Schuh  
Agent for Applicants  
Registration No. 48,180

PHARMACIA CORPORATION  
of Pfizer Inc.  
Corporate Patent Department  
P.O. Box 1027  
Chesterfield, Missouri 63336  
314-274-8182